



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Safety & Efficacy of Directly Acting
Antivirals (Sofosbuvir & Daclatasvir) in
Treatment of Chronic HCV in HIV-HCV Co-
Infected
Egyptian Patients

Thesis

Submitted for Partial Fulfillment of Master Degree
in **Gastro-Enterology and Hepatology**

By

Mahmoud Hassan Al-Sadik Hassan

M.B.B.Ch

Under Supervision of

Prof. Dr. Kadry Mohamed EL-Saeed

Professor of Gastro-enterology and Hepatology

Faculty of Medicine, Ain Shams University

Dr. Inas EL-Khedr Mohamed

Assistant Professor of Gastro-enterology and Hepatology

Faculty of Medicine, Ain Shams University

Dr. Christina Alphonse Anwar

Lecturer of Gastro-enterology and Hepatology

Faculty of Medicine, Ain Shams University

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبِحَانَكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا مَعْلَمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to Allah the Most Beneficent and Merciful.

My deepest gratitude to my supervisor, Prof. Dr. Kadry Mohamed EL-Saeed, Professor of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for his valuable guidance and expert supervision, in addition to his great deal of support and encouragement. I really have the honor to complete this work under his supervision.

I would like to express my great and deep appreciation and thanks to Dr. Inas EL-Khedr Mohamed, Assistant Professor of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for her meticulous supervision, and her patience in reviewing and correcting this work.

I must express my deepest thanks to Dr. Christina Alphonse Anwar, Lecturer of Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for guiding me throughout this work and for granting me much of her time. I greatly appreciate her efforts.

Special thanks to my Parents, my Wife and all my Family members for their continuous encouragement, enduring me and standing by me.

Mahmoud Hassan Al-Sadik Hassan

List of Contents

Title	Page No.
List of Tables.....	I
List of Figures	IV
List of Abbreviations.....	VI
Introduction	- 1 -
Aim of the Work	4
Review of Literature	
▪ Hepatitis C Virus (HCV)	5
▪ Human Immunodeficiency Virus (HIV)	42
▪ Overview of HCV/HIV Co-Infection.....	69
Patients and Methods.....	87
Results.....	93
Discussion	108
Summary	116
Conclusion	118
Recommendations	119
References	120
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Participation in Screening and HCV Seroprevalence According to Sex*	9
Table 2:	Number Screened for HCV Antibodies and Seroprevalence among Men and Women According to State.....	11
Table 3:	Geographical distribution of HCV subtypes.	19
Table 4:	Treatment recommendations for HCV-monoinfected or HCV/HIV-coinfected patients with chronic hepatitis C without cirrhosis.....	27
Table 5:	Treatment recommendations for HCV-monoinfected or HCV/HIV-coinfected patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis,	28
Table 6:	Recommended follow-up after HCV treatment according to patient characteristics.....	36
Table 7:	Patients are categorized into “easy” or “not easy” to treat groups according to pre-treatment tests:	38
Table 8:	Management of HCV treatment-experienced patients.....	39
Table 9:	ADULT Regimens for 28-day PEP for HIV Infection according to the members of the Alberta Post exposure prophylaxis Guideline Review Expert Group, 2015	57

List of Tables cont...

Table No.	Title	Page No.
Table 10:	Possible drug interactions between antiretroviral therapy and direct acting antivirals.....	80
Table 11:	Baseline demographic data of the whole studied patients.	93
Table 12:	Distribution of potential route of transmission of HIV for the whole studied patients.	95
Table 13:	Distribution of antiviral medication for hepatitis C and HIV infection for the whole studied patients.	96
Table 14:	Comparison in CBC findings, change in PT, INR and random blood sugar (RBS) over time among three groups	97
Table 15:	Comparison in liver and kidney function tests findings over time among three groups.....	98
Table 16:	Comparison of ultrasound parameters among before treatment, at the end of treatment, and SVR at 12 weeks for all included patients	100
Table 17:	HCV-PCR for the whole studied patients.....	102
Table 18:	Comparison of change in portal vein diameter over time among three groups.....	103
Table 19:	Child Pugh classification for all included patients	103
Table 20:	Comparison of change in CD4 levels over time among three groups	104

List of Tables cont...

Table No.	Title	Page No.
Table 21:	Relation between incidence of relapse, demographic characteristics and type of therapy for the whole studied patients.....	105
Table 22:	Relation between incidence of results type of DAA and studied laboratory parameters for the whole studied patients.....	106
Table 23:	Distribution of adverse effect for the whole studied patients.	107

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Prevalence of HCV seropositivity in Egypt, Egyptian DHS 2008	7
Figure 2:	Model structure of HCV and proteins encoded by HCV genome.....	15
Figure 3:	HCV receptors for cell entry	16
Figure 4:	Life cycle of HCV	18
Figure 5:	Classes of directly acting antiviral.....	26
Figure 6:	Structure of HIV virion particle	45
Figure 7:	Life cycle of HIV	48
Figure 8:	Improvements in hepatitis C virus (HCV) treatment and narrowed gap in SVR between HIV/HCV coinfecting and HCV mono-infected persons (genotype 1, treatment-naïve).	77
Figure 9:	Mean value of age (year) and distribution of gender (number) of the whole studied patients.....	94
Figure 10:	Distribution of marital status, occupation, and special habits of the whole studied patients.....	94
Figure 11:	Distribution of potential route of HIV transmission for the whole studied patients.....	95
Figure 12:	Mean values of ALT and AST levels over time among the studied patients.....	99
Figure 13:	Ultrasound parameters in before treatment, at the end of treatment, and SVR at 12 weeks for all included patients.....	101

List of Figures cont...

Fig. No.	Title	Page No.
Figure 14:	Distribution of HCV-PCR among the studied patients before treatment, by the end of treatment and SVR at 12 weeks.....	102
Figure 15:	Mean values of change in CD4 levels over time in three groups.....	104
Figure 16:	Distribution of adverse effect for the whole studied patients.....	107

List of Abbreviations

Abb.	Full term
<i>ABC</i>	<i>Abacavir</i>
<i>AFP</i>	<i>Alfa feto protein</i>
<i>AHI</i>	<i>Acute HIV-1 infection</i>
<i>AIDS</i>	<i>Acquired immunodeficiency syndrome</i>
<i>ARVs</i>	<i>Antiretrovirals</i>
<i>ATV/r</i>	<i>Atazanavir/Ritonavir</i>
<i>AZT</i>	<i>Zidovudine</i>
<i>BCRP</i>	<i>Breast Cancer Resistance Protein</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CYP</i>	<i>Cytochrome P450</i>
<i>DAA</i>	<i>Direct-acting antiviral</i>
<i>DAAs</i>	<i>Direct acting antivirals</i>
<i>DCV</i>	<i>Daclatasvir</i>
<i>DDIs</i>	<i>Drug-drug interactions</i>
<i>DHS</i>	<i>Demographic and Health Survey</i>
<i>DRV/r</i>	<i>Darunavir/Ritonavir</i>
<i>DSV</i>	<i>Dasabuvir</i>
<i>DTG</i>	<i>Dolutegravir</i>
<i>EBR</i>	<i>Elbasvir</i>
<i>eGFR</i>	<i>Estimated glomerular filtration rate</i>
<i>EHIS</i>	<i>Egyptian Health Issues Survey</i>
<i>EFV</i>	<i>Efavirenz</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>FTC</i>	<i>Emtricitabine</i>
<i>GLE</i>	<i>Glecaprevir</i>
<i>GZR</i>	<i>Grazoprevir</i>
<i>HAART</i>	<i>Highly active antiretroviral therapy</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>

List of Abbreviations cont...

Abb.	Full term
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HIV</i>	<i>Human Immunodeficiency Virus</i>
<i>HIV-1</i>	<i>Human Immuno-deficiency Virus type I</i>
<i>IDU</i>	<i>Intravenous Drug Use</i>
<i>IRIS</i>	<i>Immune Reconstitution Inflammatory Syndrome</i>
<i>LDLr</i>	<i>Low Density Lipoprotein receptor</i>
<i>LDV</i>	<i>Ledipasvir</i>
<i>LPV/r</i>	<i>Lopinavir/Ritonavir</i>
<i>NCCVH</i>	<i>National Committee for Control of Viral Hepatitis</i>
<i>NNRTIs</i>	<i>Non-Nucleoside Reverse Transcriptase Inhibitors</i>
<i>NRTIs</i>	<i>Nucleoside analogue reverse transcriptase inhibitors</i>
<i>NUC</i>	<i>Nucleoside or nucleotide analogue</i>
<i>NVP</i>	<i>Nevirapine</i>
<i>OATP1B1</i>	<i>Organic anion transporting polypeptide B1</i>
<i>OBV</i>	<i>Ombitasvir</i>
<i>PAT</i>	<i>Parenteral anti-schistosomiasis treatment</i>
<i>PEP</i>	<i>Post exposure prophylaxis</i>
<i>PI</i>	<i>Protease inhibitors</i>
<i>PIB</i>	<i>Pibrentasvir</i>
<i>PIs</i>	<i>Protease Inhibitors</i>
<i>PTV</i>	<i>Paritaprevir</i>
<i>PWIDs</i>	<i>People who inject drugs</i>
<i>R</i>	<i>Ritonavir</i>
<i>RBV</i>	<i>Ribavirin</i>

List of Abbreviations *cont...*

<i>Abb.</i>	<i>Full term</i>
<i>RNA</i>	<i>Ribonucleic acid</i>
<i>RT</i>	<i>Reverse transcriptase p66</i>
<i>SOF</i>	<i>Sofosbuvir</i>
<i>SPSS</i>	<i>Statistical SPSS Package program</i>
<i>SR-B1</i>	<i>Scavenger Receptor class B1</i>
<i>SVR</i>	<i>Sustained virological response</i>
<i>TDF</i>	<i>Tenofovir</i>
<i>UNAIDS</i>	<i>United Nations Program on HIV/AIDS</i>
<i>vDNA</i>	<i>Viral DNA intermediate</i>
<i>VEL</i>	<i>Velpatasvir</i>
<i>VOX</i>	<i>Voxilaprevir</i>
<i>WHO</i>	<i>World Health Organization</i>
<i>3TC</i>	<i>Lamivudine</i>